Valence8 US’s Enanta Pharmaceuticals ENTA Stock Holding History

Valence8 US’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,939	Closed	-$207K	–	30
2024 Q3	$207K	Buy	+19,939	New	+$261K	0.09%	43

Other funds holding ENTA

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Valence8 US's ENTA Position: Q4 2024 in Review

Valence8 US sold out of Enanta Pharmaceuticals (ENTA) in Q4 2024, closing a stake of 19,939 shares — an estimated $207K sold.

Valence8 US first reported a position in ENTA in Q3 2024 and held it in 1 quarter. The position peaked at $207K in Q3 2024. 107 funds tracked by Wall St. Rank hold ENTA as of Q4 2024.

Valence8 US reported no remaining Enanta Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 19,939 Enanta Pharmaceuticals shares in Q4 2024, an estimated $207K.
Valence8 US first reported a position in Enanta Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Valence8 US's Enanta Pharmaceuticals position peaked at $207K in Q3 2024.
107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.